Despite the many innovations that have occurred in cancer treatment, the age-specific mortality for most adult tumors has remained stable during the past 30 years. There have been clinically significant improvements in the outcomes of young and middle-aged patients, yet the vast majority of cancer patients are more than 50 years of age, among whom we observe few improvements in clinical outcomes. Clearly, many of today's cytotoxic agents have been shown to be effective in-vitro and in animal model systems; however, few have proved efficacious in dramatically improving survival outcomes in adult cancer. There is now increasing evidence to suggest that the administration of cytotoxic agents, at the appropriate circadian phase, can significantly increase the therapeutic index of current cancer therapies.
The Science of Chronobiology-Timing Is Everything
Chronobiology is the quantitative study of rhythmic temporal relationships in biological phenomena. The most basic studies of biodynamics demonstrate that biophysical and biochemical processes vary with time in a predictable and periodic manner. During the past 50 years, biologists have discovered that periodic processes regulate biochemical and physiological behaviors. 1 Many important biological chemical signals are released as pulses where the signal duration is brief compared to the elicited behavior. For example, signals inducing chemotaxis last only a few seconds, while eliciting a cell movement step of several minutes; conversely, an interleukin-2 pulse lasts several minutes to induce a proliferation in T-cells. Rhythms in the concentrations of biological signals and physiological processes are found to regulate many biologic behaviors, including processes governing glycolysis, mitosis, aggregation, pacemaker activity, the menstrual cycle, and metabolism. 2, 3 Indeed, recent research indicates that almost all mammalian cellular and physiological processes are under circadian regulation. 4 The discovery that circadian rhythms are internally generated was De Mairan's early 18th century observations-that the leaves of the mimosa plant open during the day and close at night and that this pattern continues in constant darkness. 1 Biologists have found in mammals under constant darkness an activity rhythm with a periodicity slightly different from 24 hours. 5 Today we know that circadian rhythms are found in organisms ranging from photosynthetic algae to humans and everything in between. In mammals, many hormonal and chemical signals exhibit a 24hour period in pulse release. This periodicity led to the hypothesis that internally generated circadian rhythms regulate, and integrate, many biological activities of mammalian daily life. Indeed, there are extensive data showing that endogenous gene-based circadian organization is a fundamental property of human physiology and pathophysiology. 6 Many biological systems have independently evolved circadian clocks. The adaptation of the day/ light cycle provides the organism with valuable information required to meet the demands of daily life. Indeed, homeostatic processes demand a flexible, yet well-coordinated, internal time structure. For example, a predictable internal periodic cycle ensures that if a critical event fails to occur within a cycle, this event can occur in the subsequent cycle.
Today, scientists from many specialties are making incredible progress in understanding the circadian rhythm. In fact, we now understand that evolutionary processes have adapted circadian rhythms to integrate the key physiological processes of daily life. For example, sleep/wake and nutrition cycles play a critical role in helping us adapt to our periodically changing environment. 4 During the past 10 years, there has been major progress in our understanding of the physiological, cellular, and molecular mechanisms regulating circadian rhythms. Through genetic analysis of organisms ranging from unicellular to plants, invertebrates, and mammals, scientists are now isolating the biochemical, genetic, and cellular functions of circadian mechanisms. [6] [7] [8] 
The Regulation of Daily Life by Circadian Rhythms
Several research groups have published data revealing the existence of tissue-specific patterns of circadian rhythmicity in higher animals. 8, 9 Panda et al 8 found that nearly all circadian-regulated genes in the suprachiasmatic nucleus (SCN) and liver were different. Indeed, they discovered that only 28 of the 650 identified circadian-regulated genes in the SCN and liver were shared and that these genes govern organspecific physiological functions. For example, they found a number of circadian-regulated genes in the SCN that governed locomotor activity. In the liver, these genes govern a variety of pathways involved in energy storage and generation; in addition, the production of thyroid T3 hormone, the photopigment retinol, the regulation of drug metabolic pathways, and the components for coagulation and fibrinolytic pathways are under the regulation of circadianexpressed genes. 10 These observations account for the circadian patterns of toxicity and bioavailability of a large number of drugs and drug metabolites. 11 The result of this research will be the identification of unique sets of circadian-regulated genes for each organ in the human body.
Aberrant Endogenous Circadian Function in Cancer Induction and Progression
There is accumulating evidence that defects in the daily oscillations of circadian rhythms enhance cancer risk. Well-controlled animal experiments show that environments that eliminate circadian integration of organ function accelerate the development of tumors in rodents. 12 In human studies, epidemiologists have found that shift work elevates individuals' risk for a variety of diseases, particularly breast cancer.
During the past 10 years, scientists have identified the genes involved in regulating mammalian circadian clocks. Molecular biologists are beginning to link the genes known to participate in circadian clock function with the regulation of cell proliferation. This should not be surprising, as some of the circadian clock genes are transcription factors. 13 We have already observed that the circadian clock controls downstream cellular events by governing the expression of clock-controlled genes that function in the rate-limiting steps of various biological pathways. 8 There is accumulating evidence that clock genes regulate cellular proliferation and apoptosis in rapidly renewing tissues. 14, 15 
Circadian Rhythms and Cancer Biology
In cancer, the equilibrium between cell proliferation and cell death has shifted to excessive proliferation and/or a diminished rate of cell death. Circadian processes influence the molecular and cellular mechanisms regulating mitosis and programmed cell death. 16 It is clear that cells do not enter or exit the various cell cycle phases randomly throughout the day, but rather do so in a highly organized fashion at distinct circadian phases. Consequently, slow growing tumors often retain the circadian rhythms of the host tissue. In fast growing or advanced tumors, cellular proliferation may exhibit ultradian rhythms or may sometimes even disappear. The sampling frequency necessary to determine this disappearance with any degree of certainty is, however, not practical.
Rhythmic coordination of tissue function partially explains the circadian variation in sensitivity of rapidly proliferating tissues to the cytotoxic effects of chemotherapy. The regular circadian rhythms in cell proliferation and apoptosis within bone marrow and the gastrointestinal tract may, in part, explain the circadian phase-dependent toxicity of cell cycle phase-specific drugs. Indeed, circadian rhythms may also exist in some but not all tumors.
Murine experiments clearly indicate that whereas toxicity and dose intensity each depend upon the circadian timing of cytotoxic agents, a second, dose intensity independent, relationship also exists between circadian drug timing and anticancer efficacy. 17 Cells of the epithelial lining of the human gut and the hematopoietic precursor cells residing within the bone marrow of healthy individuals undertake the process of DNA synthesis and cell division nonrandomly within the day. 18, 19 Randomized single institution and multicenter clinical trials have consistently demonstrated that cytotoxic drug toxicity can be diminished and both dose intensity and objective tumor response frequency can be increased and cancer patient survival improved by optimal circadian drug timing. 20 If cell proliferation in spontaneous human cancer is coordinated within the day, then, since many cytotoxic drugs kill cells more or less effectively, depending upon cell cycle phase, a finding of circadian rhythm in any aspect of cancer cell proliferation would provide a mechanism supporting the likelihood that cancer cell susceptibility, itself, waxes and wanes predictably throughout each day. Furthermore, if the normal endocrine-paracrine-autocrine loops controlling circadian gating of cell proliferation are intact in cancer cells, a novel paradigm for cancer control is opened that does not require cancer cell killing. 21, 22 Determining the proportion of tumor cells residing within specific phases of the cell cycle at different times within the day currently demands frequent serial tumor sampling throughout at least one entire day. Data in cancer patients is understandably limited, but some relevant data have appeared. Voutilainen and Tähti each biopsied a variety of cancer types, around the clock, and documented time of daydependent peaks of cancer cell mitosis in the tumors of most patients, with differing circadian patterns seen in cancers of different origin. 23, 24 On average, across all tumor types, 2 daily peaks of mitosis were found, the first between midnight and 2 AM and a second smaller peak around noon. Smaaland found that malignant cells obtained, around the clock, from the involved nodes of patients with various non-Hodgkins lymphomas, on average, organize their cell proliferation late each day, with a midnight peak in S and G 2 cancer cells. 25 Klevecz concurrently sampled both malignant ovarian cells and nonmalignant nonovarian mesothelial cells from the peritoneal cavities of patients with ovarian cancer, finding different circadian organizations of these 2 cell populations arising, within the identical physiologic milieu. A higher proportion of sampled ovarian cancer cells were in G 2 and S phases in the late morning hours, whereas a larger proportion of benign peritoneal mesothelial cells inhabited these phases of the cell cycle in the late evening hours. 26 These data, limited though they are, en masse raise the possibility that circadian time structure of DNA synthesis and/or mitosis is determined not by whether a cell is benign or malignant but rather by the tissue of origin of that cell, its ontogeny. To test this hypothesis, however, benign and malignant tissue samples of the same cell type must be obtained concurrently, around the clock.
The mitotic figures of benign and malignant epidermoid cells of skin origin from an environmentally synchronized patient with metastatic cancer appear and disappear nonrandomly throughout the day. This finding supports the hypothesis that human cancer cell proliferation is organized within the day and is in keeping with the 4 relevant series in the literature. These limited data are the first to directly indicate that the cell type of cancer origin may confer specific circadian cytokinetic time-keeping characteristics upon the analogous cancer cell. Such circadian cytokinetic coordination may be an important cause of the therapeutic advantage observed by optimally timing cytotoxic cancer therapy within the day. 18 This circadian cytokinetic organization is likely to be relevant to the toxic-therapeutic ratio of irradiation, cytotoxic, biologic, and many if not all other molecular strategies with potential to control cancer. 27 If tumor tissue susceptibility to a cytotoxic drug is coordinated during the day by host circadian rhythms, therapeutic gain can be enhanced by administering a drug at the circadian phase associated with maximal tumor cell kill. Further gains in therapeutic benefit can be achieved when the circadian phase of maximal tumor kill and maximum susceptibility of the most sensitive host tissue are different. If the susceptibility of tumor tissue to cytotoxic chemotherapy is not at all or only weakly coordinated during the day by the circadian rhythms of the host, gain can be achieved by administering the cytotoxic drug at the time of day when the host tissues are least damaged by that agent. This will allow escalation of dose intensity with higherthan-average doses delivered at correspondingly lower toxicity, resulting in greater average tumor cell kill. 20, 27 
Timing in Diagnosis and Treatment
From the time of the ancient Greeks, physicians have documented the temporal patterns of disease manifestation. For example, the daily temperature rhythm appearing on each patient's hospital record is so expected that it is practically invisible; the daily pattern of sleep and activity is so mundane that it is not recognized as a circadian rhythm. Mean arterial blood pressures are well known to be highly variable, yet not recognized as circadian-dependent; when that variation is carefully inspected, however, much of it results from prominent circadian rhythms in each of these cardiovascular physiologic parameters. The large, regular daily variations in activity, body temperature, and blood pressure are often considered unconsciously in the physician's interpretation of vital signs in the general health of the patient. If not considered, these assessments will be imprecise and misleading. For example, human blood pressures in the range of 130/ 85 in the middle of the night are severely abnormal and may be ominous, whereas the same pressures in the afternoon are quite usual and unalarming.
Timing Cancer Treatment
The successful treatment of cancer requires the use of drugs with much more frequent and serious side effects than those available to modulate most chronic diseases. With the current generation of antitumor agents, the therapeutic index between benefit and toxicity is surprisingly narrow. Although oncologists have been working for decades to effectively titrate drug doses to maximize desired clinical effects while minimizing toxicities, drug toxicity remains the ratelimiting factor in treatment success. There is now sufficient evidence in animal models indicating that therapeutic effect is maximized and toxicity minimized when anticancer drugs are administered at the optimal phase of the circadian cycle. Animal experiments have found that the toxicities of many chemotherapeutic agents vary with the phase of the circadian cycle. The anticancer efficacy of these agents, either given singly or in combinations, has also been shown to be circadian-dependent. In humans, it is becoming increasingly clear that cancer therapy optimized to the individual patient requires consideration of circadian organ and cellular functions. 20 Although patient-topatient variability in optimal drug dosing is difficult to predict, within-person circadian variability for individuals living on usual societal routines is more predictable than person-to-person variability of age, sex, body size, and so on.
Recent clinical data confirm the prognostic impact of circadian function in patients with advanced cancer. Colorectal cancer patients with distorted circadian function usually have a larger tumor burden, liver metastases, and poorer performance status. On the other hand, patients with colorectal metastatic disease who have normal rest-activity circadian rhythms had a 5-fold higher 2-year survival than patients with diminished rhythms. Clearly, the restoration of a more normal circadian function and the administration of antitumor drugs at the appropriate circadian time maximize the opportunity to improve clinical outcomes. 20, 28, 29 
Clinical Data
There is now significant experimental evidence in animals and humans that shows significant advantages for "optimal" circadian scheduling in different classes of antitumor drugs. Circadian administration of the antitumor agent doxorubicin improves survival outcomes and lowers toxicity for ovarian cancer patients; circadian administration of doxorubicin is in the early morning. When doxorubicin is given in the morning, white blood cell nadirs are much less profound and recovery to baseline is complete within 21 days. When evening doxorubicin is given, full recovery does not occur within 28 days. The circadian administration of doxorubicin and cisplatin significantly improves the 5year survival of patients with advanced ovarian cancer. The circadian administration of doxorubicin in the morning followed by evening cisplatin 12 hours later resulted in a 44% 5-year survival rate. When doxorubicin is given in the evening and cisplatin is given the next morning, only 11% of the patients survived 5 years, a significant difference. 30 Reactive nucleophilic platinum-based drugs (cisplatin and oxaliplatin) are another class of potent antitumor agents with circadian dependence in anticancer activity. They are more effective when given in the evening. Forty-three patients with widely metastatic transitional cell carcinoma of the bladder were treated with high-dose intensity, circadian-timed doxorubicin (eg, morning) and cisplatin (eg, evening), followed by cyclophosphamide, 5-FU, and cisplatin maintenance for up to 2 years. 30 In this cohort, 57% of the 35 evaluable patients with widespread metastatic cancer responded objectively. Twenty-three percent (23%) had complete disappearance of all cancer. Median survival from first treatment for complete responders was more than 2 years and 1 year for partial responders. Three of the complete responders were alive without evidence of cancer more than 2 years after stopping all therapy. Highdose intensity circadian-timed combination chemotherapy can induce durable complete responders of widespread bladder cancer in the majority of treated patients with moderate toxicity and excellent quality of life.
Antimetabolites (5-FU, FUDR, 6 mercaptopurine, and methotrexate) are most effective when given in the evening hours or early in the daily sleep span, when DNA synthesis in bone marrow and gut is minimal. In a phase III study, 116 patients with metastatic renal cell cancer were randomized to a flat or circadian-modified infusion of FUDR for 14 days every 28 days. In this trial, 104 patients were available for data analysis. 30 In the circadian-modified arm, 65% of the daily dose was given from 8 PM to 2 AM. The starting dose was 0.125 mg/kg/d.
They received a median of 3 courses of chemotherapy (1 to 22 courses), and the median follow-up of surviving patients was 12 months. Diarrhea, the doselimiting toxicity, was less frequent in the circadianmodified arm. There were 2 deaths related to dehydration caused by diarrhea. The median dose by the fifth course was 0.175 mg/kg/d. More dose escalation was achieved and less dose reduction was required in the circadian-modified arm. One CR and 10 PR were observed (objective response rate; 11.5%). Responses continued in 8/11 patients at a median of 12 months. An additional 12 patients (11.5%) remained progressionfree for more than 1 year. At 1 year, failure-free survival was 35% and overall survival 45%. The difference in toxicity between flat and circadian-modified infusion FUDR was validated. Response rates were similar to those seen in interferon and/or interleukin-2 treatment, but more durable. 30 A recent series of phase III randomized clinical trials of untreated colorectal metastatic disease compared the administration of oxaliplatin, fluorouracil, and folinic acid at the optimal circadian phase to conventional constant-rate infusion. Ninety-three patients were assigned chronotherapy and 93 were assigned constant-rate infusion. The randomization failed, and the chronotherapy arm had a statistically significant higher fraction of patients with bone metastases (constant-rate infusion 2 patients, chronotherapy 10 patients) and relapse from surgically treated metastases (constant-rate infusion 7 patients, chronotherapy 22 patients). Clearly, the chronotherapy arm was biased toward patients with a worse than expected prognosis. Nonetheless, an objective tumor response was obtained in 47 (51%) of the chronotherapy group compared to an objective response in 27 (29%) of the constant-rate group (difference 21.5% [95% CI 13.7-31.2], P = .003). Chronotherapy was associated with a 5-fold reduction in the rate of severe mucosal toxicity (14% vs 76%, P < .0001), and the rate of peripheral neuropathy was reduced by 50% (16% vs 31%, P < .01). In light of a failed randomization, the median survival times and 3year survival were similar in both groups (15.9 vs 16.9 months and 22% vs 21%, respectively). 28 A follow-up clinical trial demonstrated that chronomodulated therapy could increase the dose of fluorouracil and 1-folinic acid in patients with untreated metastatic colorectal cancer. This trial of 1000 patients with untreated or inoperable metastatic disease received a chronomodulated daily infusion of therapy where the dose was escalated until patients exhibited toxicity. The tumor response rate was 41%, and many patients' tumor shrank to the extent that surgery became possible. The median survival of these patients was 17 months, but 28% achieved a 2-year survival and 18.6% a 3-year survival. Tumor response achieved with intensified chronomodulated delivery of 5-FU/l-FA was nearly twice as high as that obtained by earlier clinical trials organized by this cooperative group, using less intensive 5-FU/FA chronotherapy. 29 These multicenter trials found that administering chemotherapy at their optimal circadian phase was significantly less toxic and more effective than constant-rate infusion. High efficacy and good tolerability permitted secondary surgical resection of previously inoperable metastases, with apparent survival improvement (3-year survival > 20%). Indeed, these findings suggest that clinical outcomes in metastatic colorectal cancer patients can be optimized by combining chronotherapy with surgery. 31 The positive benefits of chronotherapy were also reported in a phase II trial of 23 advanced pancreatic cancer patients who were administered 5-fluorouracil (5-FU) chemoradiation at the optimal circadian phase. Six patients were unresectable and 17 were treated postoperatively. The median external beam irradiation dose was 50.4 Gy. 5-FU infusion was given 5 days per week (300 mg/m2/d) and the median total dose was 8.4 g/m2. Chronomodulated 5-FU infusion consists of a low basal infusion rate for 16 hours followed by an 8-hour escalating-de-escalating infusion peaking at 10 PM. Twelve of 17 patients treated postoperatively were locally controlled, and 7 patients had no evidence of disease. The median survival was 28 months with a 1-year actuarial survival of 88% in the group of resected patients. The 6 patients treated for unresectable disease had a median survival of 13 months. These are impressive results considering the dismal prognosis associated with advanced pancreatic cancer. 32 In a trial of 200 patients with metastatic colorectal cancer, the relationship between patient rest/activity cycles and quality of life (QOL) was investigated; QOL is becoming an increasingly more important outcome for patients with advanced cancer. In this study, patients' circadian rest/activity cycle was measured using a wrist actigraph 3-5 days before chronotherapy, and QOL was measured using the European Organization for Research and Treatment of Cancer (QLQ-C30) plus the Hospital Anxiety and Depression Scale. The investigator found that intact circadian rhythms correlated with better scores in global QOL as well as physical, emotional, and social functioning. In addition, they found that a negative aberrant rest/activity cycle identified patients with greater levels of fatigue, appetite loss, and nausea. In aggregate, these data indicate that intact circadian rhythms are linked to QOL in patients with advanced cancer. 33 Corticosteroids and interferons are less toxic with no loss of effectiveness against cancer when given upon awakening and just before sleep. Preclinical data are also becoming available, which demonstrate that the circadian timing of growth factors and biologic response modifiers (erythropoietin, granulocyte colony stimulating factor, and interleukin-2) is substantially more critical than the timing of common cytotoxic therapeutic agents. There is more than a 10fold difference in the bioactivity of these peptides when administered at different phases of the circadian cycle; see Table 1 for data on circadian timing of anticancer agents.
Chronobiology and Anticancer Drug Development
Anticancer drug development is a complex, expensive, high-risk venture with a surprisingly small market. Compounds are screened for cytotoxicity, analogs are developed, or agents are designed and synthesized to target certain critical cellular events or pathways. Compounds move through a "decision network" drug development process with many steps. At each step, most of the candidate agents are discarded for reasons related to toxicology, lack of specificity, or efficacy. The few agents that graduate from in vitro screening to whole animal systems have high subsequent probabilities of failure as they move through in-vivo toxicology trials in the mouse, rat, dog, and primate, or during concurrent efficacy evaluation in human tumor cell lines and mouse tumor model systems. If the target of drug action in host cells is virtually present or absent at specific times of the day, the results of screening studies will be divergent depending upon when in the day they are performed. An example is the development of a new S-phase active agent whose subcellular target is thymidylate synthase, the enzyme required for de novo synthesis of thymidine, which is necessary for DNA replication. If the toxicology of the agent is evaluated at the time of day associated with little gut or bone marrow DNA synthesis activity, the agent will have an excellent toxic/therapeutic ratio.
In fact, the time of day that these studies are usually performed is in the first half of the "working day." This time of day generally corresponds to the first half of the mouse's daily sleep span, when relatively low levels of DNA synthetic activity are occurring in both gut and bone marrow. Phase I clinical trials are also carried out in the first half of the working day, during the cancer patient's diurnal activity span, when human gut and bone marrow each exhibit the highest level of daily DNA synthetic activity. The resultant apparent poor therapeutic index might well cause this agent to be discarded as too toxic. Consequently, ignoring the implications of circadian rhythms means a subsequent loss of powerful therapies and increased cost of drug development.
Data suggest that this scenario could be different if preclinical studies demonstrated the optimum circadian time for therapy and if subsequent phase I trials were performed using these circadian data. Since efficacy is nonlinearly related to treatment timing, the circadian timing of drug administration in phase II and phase III studies is likewise critical in maximizing drug efficacy. Drug delivery strategies to optimize the precise timing of cytotoxic agents, growth factors, and biological response modifiers are being rapidly developed. These strategies and the delivery systems that will allow them to be effectively and transparently employed will add tremendous value to cancer therapeutics. For some agents, they will make the difference between efficacy and no effect. It is likely that the antitumor effects of novel biological agents now 
Conclusion
This article describes an integrative non-drugbased approach to maximizing anticancer efficacy while diminishing unwanted side effects-circadian cancer chronotherapy. We now know that every cell in the human body has a circadian clock. These clocks are under the control of a master clock located in the SCN. Furthermore, circadian clocks regulate the function of all tissues in our body, including neoplastic growths. Indeed, the molecular mechanisms of the circadian clocks are intimately involved in the regulation of cell proliferation, differentiation, and programmed cell death. The biological rationale for applying circadian rules to clinical treatment is therefore compelling. Indeed, we now have extensive evidence demonstrating that the circadian-timed antitumor therapy significantly improves survival and quality of life in patients with advanced cancer. In this article, we review evidence that shows we can greatly improve clinical outcomes by integrating the patients' circadian rhythms into our treatment protocols.
To fully exploit the capabilities of our future targeted anticancer agents, drug development programs must identify the optimal timing for administration. After all, in life, timing is everything.
